Titanium 4000 — Class I drug recall D-1292-2019
Terminated recall by D.B.P. Distribution, reported 2019-05-22, distributed nationwide. Marketed without an approved NDA/ANDA: undeclared sildenafil and tadalafil.
| Recall number | D-1292-2019 |
|---|---|
| Product type | Drug |
| Classification | Class I |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | D.B.P. Distribution, Chatsworth, CA, United States |
| Recall initiated | 2019-04-23 |
| Classified | 2019-05-22 |
| Reported by FDA | 2019-05-22 |
| Terminated | 2023-03-07 |
| Distributed | Nationwide (US) |
| Reason classes | undeclared allergen, unapproved product |
| Expiration dates | 2020-12-29 |
Product
Titanium 4000, capsule, 4000 mg, 1 count blister card, 30 blister display boxt, distributed by Titanium 4000 UPC 86077000020
Reason for recall
Marketed without an approved NDA/ANDA: undeclared sildenafil and tadalafil.
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-1292-2019. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.